Geode Capital Management LLC Buys 264,825 Shares of Savara Inc (NASDAQ:SVRA)

Geode Capital Management LLC lifted its position in Savara Inc (NASDAQ:SVRA - Free Report) by 10.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,726,850 shares of the company's stock after buying an additional 264,825 shares during the quarter. Geode Capital Management LLC owned about 1.59% of Savara worth $11,564,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. The Manufacturers Life Insurance Company lifted its position in Savara by 9.0% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 44,956 shares of the company's stock worth $191,000 after acquiring an additional 3,706 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Savara by 5.1% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,815 shares of the company's stock valued at $533,000 after purchasing an additional 6,141 shares during the period. Principal Financial Group Inc. grew its holdings in Savara by 64.4% in the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company's stock valued at $72,000 after buying an additional 6,973 shares during the last quarter. ClariVest Asset Management LLC increased its position in Savara by 2.9% in the 2nd quarter. ClariVest Asset Management LLC now owns 256,479 shares of the company's stock worth $1,034,000 after buying an additional 7,170 shares during the period. Finally, Victory Capital Management Inc. lifted its holdings in shares of Savara by 7.0% during the third quarter. Victory Capital Management Inc. now owns 140,010 shares of the company's stock worth $594,000 after buying an additional 9,180 shares during the last quarter. 87.93% of the stock is owned by institutional investors.

Insider Activity at Savara

In other news, Director Joseph S. Mccracken purchased 20,000 shares of Savara stock in a transaction dated Tuesday, November 19th. The shares were bought at an average cost of $2.95 per share, with a total value of $59,000.00. Following the completion of the transaction, the director now directly owns 210,837 shares in the company, valued at $621,969.15. This trade represents a 10.48 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Matthew Pauls sold 54,702 shares of the company's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $3.31, for a total transaction of $181,063.62. Following the completion of the sale, the chief executive officer now owns 1,536,379 shares of the company's stock, valued at approximately $5,085,414.49. This represents a 3.44 % decrease in their position. The disclosure for this sale can be found here. 5.13% of the stock is currently owned by corporate insiders.

Savara Trading Down 0.3 %

Shares of Savara stock traded down $0.01 on Wednesday, hitting $3.07. 390,335 shares of the company's stock traded hands, compared to its average volume of 1,264,216. The firm's 50-day moving average price is $3.40 and its two-hundred day moving average price is $3.93. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The stock has a market capitalization of $526.87 million, a PE ratio of -7.14 and a beta of 0.92. Savara Inc has a one year low of $2.82 and a one year high of $5.70.

Savara (NASDAQ:SVRA - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11). On average, research analysts expect that Savara Inc will post -0.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on SVRA shares. HC Wainwright cut their target price on shares of Savara from $10.00 to $6.00 and set a "buy" rating for the company in a research note on Wednesday, November 13th. JMP Securities reissued a "market outperform" rating and set a $9.00 target price on shares of Savara in a research report on Thursday, December 19th. Evercore ISI reaffirmed an "in-line" rating and issued a $5.00 price target (down previously from $7.00) on shares of Savara in a report on Wednesday, November 13th. Finally, Wells Fargo & Company started coverage on Savara in a report on Friday, December 20th. They set an "overweight" rating and a $8.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, Savara currently has a consensus rating of "Moderate Buy" and a consensus target price of $9.86.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.